Table 9.
Kinetics of immune responses post third dose by study vaccine and priming vaccine schedule among the modified intention-to-treat population of immunology cohort, group B
|
Prime with ChAd/ChAd |
Prime with BNT/BNT |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control (n=23) | BNT (n=23) | VLA (n=23) | VLA half (n=27) | Ad26 (n=24) | Control (n=23) | BNT (n=23) | VLA (n=20) | VLA half (n=24) | Ad26 (n=19) | |
| SARS-CoV-2 anti-spike IgG, ELU/mL | ||||||||||
| Day 0 | 1276 (945–1723; n=23) | 1443 (1051–1982; n=23) | 1211 (744–1971; n=23) | 1334 (899–1981; n=27) | 1555 (1037–2331; n=24) | 4483 (3153–6374; n=23) | 5422 (3781–7776; n=23) | 3352 (1814–6194; n=20) | 3460 (2322–5156; n=24) | 4181 (3037–5756; n=19) |
| Day 7 | 1080 (808–1443; n=23) | 15 524 (10 938–22 033; n=23) | 1299 (829–2036; n=23) | 1292 (912–1830; n=27) | 2735 (2023–3697; n=24) | 3852 (2797–5303; n=23) | 27 551 (21 016–36 118; n=23) | 3829 (2620–5595; n=20) | 3415 (2506–4653; n=24) | 7726 (5592–10 675; n=19) |
| Day 28 | 867 (634–1186; n=23 | 21 824 (16 938–28 119; n=23) | 1599 (988–2589; n=23) | 1537 (1054–2243; n=27) | 5673 (4078–7892; n=24) | 3209 (2338–4404; n=23) | 26 171 (21 245–32 239; n=23) | 4428 (3264–6008; n=20) | 3500 (2599–4714; n=24) | 18 631 (11 767–29 499; n=19) |
| Cellular response (wild-type), spot forming cells per 106peripheral blood mononuclear cells | ||||||||||
| Day 0 | 56·6 (33·4–95·9; n=23) | 44·2 (25·3–77·4; n=21) | 31·7 (17·3–58·2; n=23) | 35·9 (22·4–57·4; n=27) | 36·7 (21·8–61·9; n=24) | 36·6 (22·9–58·6; n=22) | 32·9 (19·5–55·3; n=23) | 21·6 (11·1–42·0; n=19) | 31·5 (18·3–54·3; n=24) | 42·1 (22·4–79·0; n=18) |
| Day 14 | 73·6 (44·1–123·0; n=22) | 131·0 (81·7–210·1; n=23) | 72·2 (45·9–113·7; n=23) | 49·8 (31·1–79·7; n=25) | 123·4 (70·2–217·0; n=22) | 38·2 (25·8–56·7; n=22) | 94·6 (59·6–150·2; n=22) | 24·3 (13·8–42·8; n=19) | 34·9 (21·0–58·0; n=24) | 114·1 (66·7–195·4; n=19) |
| Day 28 | 50·0 (30·3–82·5; n=23) | 129·4 (76·4–219·2; n=23) | 54·2 (32·3–91·2; n=22) | 64·4 (44·6–93·0; n=27) | 102·7 (64·3–164·2; n=24) | 35·7 (19·2–66·2; n=21) | 88·6 (65·7–119·4; n=22) | 34·5 (23·3–51·0; n=20) | 39·1 (22·5–68·1; n=24) | 153·2 (72·3–324·6; n=19) |
Data are geometric mean (95% CI; number of samples available). ChAd=ChAdOx1 nCoV-19 vaccine, Oxford–AstraZeneca. BNT=BNT162b2 vaccine, Pfizer–BioNTech. Control=quadrivalent meningococcal conjugate vaccine. VLA=VLA2001 vaccine, Valneva. VLA half=half dose of VLA2001 vaccine. Ad26=Ad26.COV2.S vaccine, Janssen. ELU=ELISA laboratory units.